ÂÜŔňÂŇÂ×

Ms. Newman joined Agios in 2018 as vice president, rare disease program leadership and became chief business officer in January 2022, leading corporate strategy and business development in addition to continued program leadership across Agios’ portfolio. In her role, she is instrumental in translating Agios’ purpose, vision and culture into results that impact patients’ lives. She brings more than 22 years of industry experience with roles of increasing impact within both R&D and global commercial operations with a focus on building value creation strategies, delivering on their potential through effective execution and managing high performing matrixed teams. Prior to joining Agios she served as vice president and asset executive, Alzheimer’s disease, and vice president, R&D portfolio leadership at Biogen in Cambridge, Mass. Previously she worked in the United Kingdom in clinical development and operations at Provensis Ltd, a BTG International Group Company and G.D Searle and Company, a Division of Monsanto. Ms. Newman earned a Bachelor’s degree in Animal Physiology with Biochemistry from the University of Leicester in the UK.